BioPharm Update: Very interesting 1st Update story
Post# of 22755
(Total Views: 292)
Posted On: 07/27/2017 9:21:09 PM
BioPharm Update: Very interesting 1st Update story.
AstraZeneca plc (ADR) (NYSE:AZN) suffered a major collapse in its share price, closing down 15% to $28.88. The company announced that Progression-free survival (PFS) results from its Phase 3 MYSTIC trial of Imfinzi (durvalumab) and tremelimumab did not meet the primary endpoint of improving PFS in patients with first-line non-small cell lung cancer. Regarded as its key catalyst for the year, the poor data erased over $10b from its market cap. Merck & Co., Inc., (NYSE: MRK), on the other hand saw its shares rise on the news, with a potential competitor potentially out of the race. Shares of Bristol-Myers Squibb Co (NYSE:BMY) parred back early losses to close down 3.1% to $54.24 as concerns surfaced about its CM227 Phase 3 trial of Opdivo + Yervoy in patients with non-small cell lung cancer.
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) announced that it intends sell shares and warrants in an underwritten public offering. Shares are trading down 19% to $0.79 in the after-hours session.
Agile Therapeutics, Inc. (Nasdaq:AGRX) announced that the FDA has accepted its New Drug Application (NDA) resubmission for its contraceptive patch, Twirla. The company received a Complete Response Letter (CRL) in February 2013. The PDUFA date is December 26, 2017. Shares are trading up 13% to $4.60 in the after-hours session.
Neuralstem, Inc. (Nasdaq:CUR) announced the pricing of an underwritten public offering of 3m shares and warrants to purchase up to 2.25m shares at a purchase price of $2.00 per share and accompanying warrant, for gross proceeds of $6m. Shares closed down 29% to $1.75.
IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) shares slumped to close down 45% to $1.36 following Wednesday’s Advisory Committee meeting vote, 22-1 against recommending approval of Rexista, a generic abuse and alcohol-deterrent controlled-release oral formulation of oxycodone hydrochloride for the relief of pain.
Advanced Accelerator Applications S.A. (NASDAQ:AAAP) announced the resubmission of its New Drug Application (NDA) for Lutathera to the FDA. The resubmission follows the receipt of a Complete Response Letter (CRL) from the FDA in December 2016.
Other Major price movers (stocks priced > $1.00, volume > 100k):
Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume INCLUDING sub-$1 stocks.
ADVANCERS:
Capricor Therapeutics Inc (NASDAQ:CAPR): $1.30; +29%.
Cerus Corporation (NASDAQ:CERS): $2.40; +10%.
Zymeworks Inc (NYSE:ZYME): $7.76; +9%.
Kitov Pharmaceuticals Holdings (NASDAQ:KTOV): $2.26; +9%.
Moleculin Biotech Inc (NASDAQ:MBRX): $2:36; +8%.
DECLINERS:
Agenus Inc (NASDAQ:AGEN): $4.48; -15%.
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH): $6.96; -12%.
Dynavax Technologies Corporation (NASDAQ
VAX): $9.25; -11%.
Arca Biopharma Inc (NASDAQ:ABIO): $2.12; -11%.
Ocera Therapeutics Inc (NASDAQ:OCRX): $1.07; -8%.
AstraZeneca plc (ADR) (NYSE:AZN) suffered a major collapse in its share price, closing down 15% to $28.88. The company announced that Progression-free survival (PFS) results from its Phase 3 MYSTIC trial of Imfinzi (durvalumab) and tremelimumab did not meet the primary endpoint of improving PFS in patients with first-line non-small cell lung cancer. Regarded as its key catalyst for the year, the poor data erased over $10b from its market cap. Merck & Co., Inc., (NYSE: MRK), on the other hand saw its shares rise on the news, with a potential competitor potentially out of the race. Shares of Bristol-Myers Squibb Co (NYSE:BMY) parred back early losses to close down 3.1% to $54.24 as concerns surfaced about its CM227 Phase 3 trial of Opdivo + Yervoy in patients with non-small cell lung cancer.
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) announced that it intends sell shares and warrants in an underwritten public offering. Shares are trading down 19% to $0.79 in the after-hours session.
Agile Therapeutics, Inc. (Nasdaq:AGRX) announced that the FDA has accepted its New Drug Application (NDA) resubmission for its contraceptive patch, Twirla. The company received a Complete Response Letter (CRL) in February 2013. The PDUFA date is December 26, 2017. Shares are trading up 13% to $4.60 in the after-hours session.
Neuralstem, Inc. (Nasdaq:CUR) announced the pricing of an underwritten public offering of 3m shares and warrants to purchase up to 2.25m shares at a purchase price of $2.00 per share and accompanying warrant, for gross proceeds of $6m. Shares closed down 29% to $1.75.
IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) shares slumped to close down 45% to $1.36 following Wednesday’s Advisory Committee meeting vote, 22-1 against recommending approval of Rexista, a generic abuse and alcohol-deterrent controlled-release oral formulation of oxycodone hydrochloride for the relief of pain.
Advanced Accelerator Applications S.A. (NASDAQ:AAAP) announced the resubmission of its New Drug Application (NDA) for Lutathera to the FDA. The resubmission follows the receipt of a Complete Response Letter (CRL) from the FDA in December 2016.
Other Major price movers (stocks priced > $1.00, volume > 100k):
Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume INCLUDING sub-$1 stocks.
ADVANCERS:
Capricor Therapeutics Inc (NASDAQ:CAPR): $1.30; +29%.
Cerus Corporation (NASDAQ:CERS): $2.40; +10%.
Zymeworks Inc (NYSE:ZYME): $7.76; +9%.
Kitov Pharmaceuticals Holdings (NASDAQ:KTOV): $2.26; +9%.
Moleculin Biotech Inc (NASDAQ:MBRX): $2:36; +8%.
DECLINERS:
Agenus Inc (NASDAQ:AGEN): $4.48; -15%.
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH): $6.96; -12%.
Dynavax Technologies Corporation (NASDAQ
VAX): $9.25; -11%. Arca Biopharma Inc (NASDAQ:ABIO): $2.12; -11%.
Ocera Therapeutics Inc (NASDAQ:OCRX): $1.07; -8%.
(0)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
Scroll down for more posts ▼